Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Brendan Bender und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Antigens, CD20, Lymphoma, B-Cell, Antibodies, Bispecific. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Mosunetuzumab (Mosun) is a CD20xCD3 T‐cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step‐up dose regimen of 1/2/60/30 mg IV is designed to mitigate cytokine release syndrome (CRS) and maximize efficacy in early cycles. A population pharmacokinetic (popPK) model was developed from 439 patients with relapsed/refractory B‐Cell Non‐Hodgkin lymphoma receiving Mosun IV monotherapy, including fixed dosing (0.05–2.8 mg IV every 3 weeks (q3w)) and Cycle 1 step‐up dosing groups (0.4/1/2.8–1/2/60/30 mg IV q3w). Prior to Mosun treatment, ~50% of patients had residual levels of anti‐CD20 drugs (e.g., rituximab or obinutuzumab) from prior treatment. CD20 receptor binding dynamics and rituximab/obinutuzumab PK were incorporated into the model to calculate the Mosun CD20 receptor occupancy percentage (RO%) over time. A two‐compartment model with time‐dependent clearance (CL) best described the data. The typical patient had an initial CL of 1.08 L/day, transitioning to a steady‐state CL of 0.584 L/day. Statistically relevant covariates on PK parameters included body weight, albumin, sex, tumor burden, and baseline anti‐CD20 drug concentration; no covariate was found to have a clinically relevant impact on exposure at the approved dose. Mosun CD20 RO% was highly variable, attributed to the large variability in residual baseline anti‐CD20 drug concentration (median = 10 μg/mL). The 60 mg loading doses increased Mosun CD20 RO% in Cycle 1, providing efficacious exposures in the presence of the competing anti‐CD20 drugs. PopPK model simulations, investigating Mosun dose delays, informed treatment resumption protocols to ensure CRS mitigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
- Certara Strategic Consulting, Paris, France.
- Department of Product Development Oncology, Genentech Inc., South San Francisco, California, USA.
ORCID-Profile: Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Zitieren
APA
Bender, B., Li, C. C., Marchand, M., Turner, D. C., Li, F., Vadhavkar, S., Wang, B., Deng, R., Lu, J., Jin, J., Li, C., Yin, S., Wei, M., & Chanu, P. (2024). Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma. Clinical and Translational Science. https://doi.org/10.1111/cts.13825
Vancouver
Bender B, Li CC, Marchand M, Turner DC, Li F, Vadhavkar S, et al. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma. Clinical and Translational Science. 2024. doi:10.1111/cts.13825
BibTeX
@article{Bender2024,
author = {Bender, Brendan and Li, Chi-Chung and Marchand, Mathilde and Turner, David C and Li, Feifei and Vadhavkar, Shweta and Wang, Bei and Deng, Rong and Lu, James and Jin, Jin and Li, Chunze and Yin, Shen and Wei, Michael and Chanu, Pascal},
title = {Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13825}
}
EUVIMED